Cytokinetics shares soar on solid data from clinical trial of heart failure drug

After burning through close to $2 billion over 25 years, the company is on the cusp of asking regulators to make aficamten its first approved drug.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news